Topic: infectious respiratory diseases
Protection against active pulmonary tuberculosis disease remained up around 50%, suggesting the candidate provides lasting immunity.
The vaccine is built on computationally designed self-assembling VLP technology that Icosavax thinks can eliminate barriers to protecting against RSV.
The series A equips Meissa to run phase 1 and 2 trials of a RSV vaccine while advancing other candidates based on its synthetic biology technology.
Vir Biotechnology is gunning for a $100 million IPO as it looks to boost its work on infectious diseases and bring George Scangos back to Wall Street.
The writedown comes months after J&J took a $630 million hit tied to the suspension of clinical development of AL-8176.
Novavax’s RSV shot missed another phase 3 trial, causing the company’s stock price to lose about two-thirds of its remaining value premarket.
Aradigm’s bid to get an inhaled antibiotic to market seems at an end, with its assets up for sale and the jobs of two primary executives terminated.
U.K. biotech hVIVO is on course to start a phase 3 program for a flu vaccine that doesn’t need to have its composition tweaked every year.
Four years ago, J&J splashed out $1.75 billion to take control of antiviral firm Alios, but the lead drug from that deal now seems to be in trouble.
Insights into how bacteria hibernate and use metals to evade destruction by antibiotics could be useful in drug development.